STING1 and cancer: Overall, these findings provide compelling evidence that STING agonists, when co‐encapsulated with DNA‐damaging chemotherapeutic agents in rationally designed delivery systems, can synergistically enhance antitumor immunity, offering a promising strategy for combined cancer therapy.